RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated <i>EGFR</i>-Mutated Metastatic NSCLC.

ABSTRACT:

Introduction

Ramucirumab (RAM) plus gefitinib (GEF) exhibited favorable efficacy and safety as first-line treatment in the primary analysis of the RELAY+ study of East Asian patients with metastatic EGFR-mutated NSCLC. We report the final overall survival (OS) and safety.

Methods

This open-label, two-period, single-arm exploratory study included patients with untreated NSCLC having EGFR ex19del or L858R mutations and no central nervous system metastasis or EGFR T790M mutation. Patients received RAM (10 mg/kg every 2 wk) plus GEF (250 mg once daily) until disease progression (period 1); patients with disease progression who acquired a T790M mutation received RAM plus osimertinib (80 mg once daily) (period 2).

Results

At final OS data cutoff (Octobe

SUBMITTER: Nishio M 

PROVIDER: S-EPMC12629876 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature